Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

for Dupixent for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Regeneron and Sanofi will launch Dupixent in the U.S. at the Wholesale ...

If approved, dupilumab would be commercialized by Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi. About Atopic Dermatitis AD is the most common form of eczema and ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY came up with positive detailed results from a phase III trial on Dupixent for the indication of atopic dermatitis in adolescents at in ...

Sanofi and Regeneron want to stop bullying around atopic dermatitis. So this fall, the drugmaker partners launched the “Agents of Change” AD Challenge and asked people to submit ideas.

Patients with atopic dermatitis, particularly moderate-to ... Supported by Sanofi and Regeneron Pharmaceuticals. Dr. Simpson reports receiving consulting fees from Celgene, Anacor Pharmaceuticals ...

Per Regeneron, there are currently no biologic medicines approved for children with severe atopic dermatitis. Dupixent is one of the key drugs for Regeneron and a label expansion will further ...

(RTTNews) - Regeneron Pharmaceuticals ... in moderate-to-severe atopic dermatitis or AD. The companies noted that the one-year Phase 3 CHRONOS study showed that patients receiving the ...